JP2017529059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529059A5 JP2017529059A5 JP2016576027A JP2016576027A JP2017529059A5 JP 2017529059 A5 JP2017529059 A5 JP 2017529059A5 JP 2016576027 A JP2016576027 A JP 2016576027A JP 2016576027 A JP2016576027 A JP 2016576027A JP 2017529059 A5 JP2017529059 A5 JP 2017529059A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- modified
- dimer
- modified gdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 239000000539 dimer Substances 0.000 claims description 26
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 21
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108010071390 Serum Albumin Proteins 0.000 claims description 9
- 102000007562 Serum Albumin Human genes 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 7
- 102220005382 rs33914470 Human genes 0.000 claims description 6
- 102220143003 rs753997345 Human genes 0.000 claims description 6
- 102220025225 rs199476363 Human genes 0.000 claims description 5
- 102220123860 rs61760902 Human genes 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102220353134 c.68G>A Human genes 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102200078418 rs1805085 Human genes 0.000 claims description 3
- 102220503690 GTP-binding protein REM 1_T94N_mutation Human genes 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 102200150805 rs1057519492 Human genes 0.000 claims description 2
- 102220230165 rs1064793071 Human genes 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102200090880 rs28933100 Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 102220058798 rs786202903 Human genes 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102200075235 rs118204106 Human genes 0.000 description 1
- 102220248744 rs145985140 Human genes 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031063P | 2014-07-30 | 2014-07-30 | |
| US62/031,063 | 2014-07-30 | ||
| US201562195908P | 2015-07-23 | 2015-07-23 | |
| US62/195,908 | 2015-07-23 | ||
| PCT/US2015/042510 WO2016018931A1 (en) | 2014-07-30 | 2015-07-28 | Compositions and methods of use for treating metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529059A JP2017529059A (ja) | 2017-10-05 |
| JP2017529059A5 true JP2017529059A5 (enExample) | 2018-09-06 |
| JP6704358B2 JP6704358B2 (ja) | 2020-06-03 |
Family
ID=55179329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016576027A Active JP6704358B2 (ja) | 2014-07-30 | 2015-07-28 | 代謝障害を治療するための組成物および使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9834586B2 (enExample) |
| EP (1) | EP3174894B1 (enExample) |
| JP (1) | JP6704358B2 (enExample) |
| KR (1) | KR20170065026A (enExample) |
| CN (1) | CN106573966B (enExample) |
| AP (1) | AP2016009663A0 (enExample) |
| AU (1) | AU2015296640B2 (enExample) |
| CA (1) | CA2953827A1 (enExample) |
| CL (1) | CL2017000201A1 (enExample) |
| CO (1) | CO2017000614A2 (enExample) |
| CR (1) | CR20170027A (enExample) |
| DO (1) | DOP2017000025A (enExample) |
| EA (1) | EA035581B1 (enExample) |
| EC (1) | ECSP17005276A (enExample) |
| ES (1) | ES2883158T3 (enExample) |
| IL (1) | IL249793B (enExample) |
| MD (1) | MD20170020A2 (enExample) |
| MX (1) | MX370115B (enExample) |
| MY (1) | MY192917A (enExample) |
| PE (1) | PE20170771A1 (enExample) |
| PH (1) | PH12017500153A1 (enExample) |
| SG (2) | SG11201700378PA (enExample) |
| SV (1) | SV2017005367A (enExample) |
| TN (1) | TN2016000578A1 (enExample) |
| TW (1) | TWI710570B (enExample) |
| UA (1) | UA123432C2 (enExample) |
| WO (1) | WO2016018931A1 (enExample) |
| ZA (1) | ZA201700311B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US10981951B2 (en) | 2014-01-31 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Therapeutics for the treatment of glaucoma |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| CN117986363A (zh) | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| EP3522911B1 (en) * | 2016-10-07 | 2021-12-08 | Beth Israel Deaconess Medical Center, Inc. | Compositions comprising relaxin and methods of use thereof |
| JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| WO2018193033A1 (en) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
| JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー／エス | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ |
| JP2021511785A (ja) | 2018-01-19 | 2021-05-13 | ペプジーン インコーポレーテッドＰｅｐｇｅｎｅ Ｉｎｃ． | 組換えポリペプチド生産用ｎ末端融合パートナーおよびこれを用いた組換えポリペプチドの生産方法 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| US12054527B2 (en) | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| EP3833974A2 (en) | 2018-08-10 | 2021-06-16 | Novartis AG | Gfral extracellular domains and methods of use |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| MY205905A (en) | 2018-10-22 | 2024-11-20 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| CA3161302A1 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| KR102899743B1 (ko) * | 2019-12-11 | 2025-12-12 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드 |
| EP4072543A4 (en) | 2019-12-12 | 2024-02-07 | Qlaris Bio, Inc. | CONTROLLED RELEASE CROMAKALIM PRODRUGS |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ |
| JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE423788T1 (de) | 1995-06-22 | 2009-03-15 | St Vincents Hosp Sydney | Neues tgf-beta-ahnliches cytokin |
| US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| CA2265444C (en) | 1996-09-11 | 2008-11-18 | Ortho-Mcneil Pharmaceutical, Inc. | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| EP1100822A1 (en) | 1998-07-23 | 2001-05-23 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| CA2372119A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| DK1266006T3 (da) * | 2000-03-22 | 2006-01-16 | Octagene Gmbh | Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2405680C (en) | 2000-04-20 | 2018-02-13 | St. Vincent's Hospital Sydney Limited | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| US7141661B2 (en) | 2000-09-08 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| WO2002062999A2 (en) | 2000-12-29 | 2002-08-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| CA2437958C (en) | 2001-03-09 | 2018-10-30 | University Of Chicago | Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| HU229910B1 (hu) | 2001-05-11 | 2014-12-29 | Amgen Inc Thousand Oaks | A TALL-1-hez kötõdõ peptidek és rokon molekulák |
| GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| EP1575512A4 (en) | 2002-11-08 | 2007-08-29 | Barnes Jewish Hospital | METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| DK2441466T3 (da) | 2004-04-13 | 2014-10-27 | St Vincents Hosp Sydney | MIC-1-inhiberende middel |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| KR20070084069A (ko) | 2004-10-08 | 2007-08-24 | 도만티스 리미티드 | Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법 |
| ES2428869T3 (es) | 2005-01-24 | 2013-11-12 | Pepscan Systems B.V. | Compuestos de unión, compuestos inmunógenos y peptidomiméticos |
| JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
| TWI428448B (zh) | 2006-03-24 | 2014-03-01 | Syntonix Pharmaceuticals Inc | 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５ |
| US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
| JP2009539767A (ja) | 2006-06-02 | 2009-11-19 | ワイス | 精製および治療方法のためのＴＧＦ−βスーパーファミリータンパク質およびペプチドの使用 |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| US20100322945A1 (en) | 2006-07-26 | 2010-12-23 | Peter Timmerman | Immunogenic compounds and protein mimics |
| KR101245877B1 (ko) | 2006-08-04 | 2013-03-20 | 메디치니쉐 호흐슐레 하노버 | Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법 |
| CA2685148C (en) | 2007-04-25 | 2014-09-09 | Stem Cells Spin Sp.Z.O.O. | New stem cell lines, their application and culture methods |
| US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| CN101896192A (zh) | 2007-10-09 | 2010-11-24 | 圣文森特医院悉尼有限公司 | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 |
| EP2208072B1 (en) | 2007-10-22 | 2015-07-01 | St Vincent's Hospital Sydney Limited | Methods of prognosis |
| EP2207798A2 (en) * | 2007-10-29 | 2010-07-21 | Virginia Tech Intellectual Properties, Inc. | Porcine dc-sign, icam-3 and lsectin and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2009087190A1 (en) | 2008-01-08 | 2009-07-16 | Roche Diagnostics Gmbh | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| EP2259802A1 (en) * | 2008-03-31 | 2010-12-15 | Glaxo Group Limited | Drug fusions and conjugates |
| EP2279419A1 (en) | 2008-05-20 | 2011-02-02 | Roche Diagnostics GmbH | Gdf-15 as biomarker in type 1 diabetes |
| EP2318844A1 (en) | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| CA2740632A1 (en) | 2008-10-31 | 2010-05-06 | St. Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
| JP2012507289A (ja) | 2008-10-31 | 2012-03-29 | ヤンセン バイオテツク，インコーポレーテツド | ヒト胚性幹細胞の膵内分泌系への分化 |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| US20100204123A1 (en) | 2009-02-12 | 2010-08-12 | Mary Elizabeth Pecquet Goad | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease |
| GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| CA2766166A1 (en) | 2009-07-08 | 2011-01-13 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
| WO2011008956A2 (en) | 2009-07-15 | 2011-01-20 | Zirus, Inc. | Mammalian genes involved in infection |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| KR101968766B1 (ko) | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | 이종 폴리펩티드의 분비를 위한 방법 및 조성물 |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
| US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
| EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
| ES2627337T3 (es) | 2010-08-26 | 2017-07-27 | F. Hoffmann-La Roche Ag | Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| JP5977814B2 (ja) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| RU2013155695A (ru) | 2011-06-30 | 2015-08-10 | Дженентек, Инк. | Препараты антител против с-мет |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US9492448B2 (en) | 2012-06-20 | 2016-11-15 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| ES3066738T3 (en) | 2012-12-21 | 2026-05-14 | Aveo Pharmaceuticals Inc | Anti-gdf15 antibodies |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| PL2970422T3 (pl) | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| CN203123206U (zh) * | 2013-04-01 | 2013-08-14 | 宋艳丽 | 一种简易式一次性防污染无菌注射器 |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
-
2015
- 2015-07-28 JP JP2016576027A patent/JP6704358B2/ja active Active
- 2015-07-28 CR CR20170027A patent/CR20170027A/es unknown
- 2015-07-28 AP AP2016009663A patent/AP2016009663A0/en unknown
- 2015-07-28 CN CN201580041716.9A patent/CN106573966B/zh not_active Expired - Fee Related
- 2015-07-28 MY MYPI2017700310A patent/MY192917A/en unknown
- 2015-07-28 UA UAA201700670A patent/UA123432C2/uk unknown
- 2015-07-28 WO PCT/US2015/042510 patent/WO2016018931A1/en not_active Ceased
- 2015-07-28 TW TW104124401A patent/TWI710570B/zh active
- 2015-07-28 MX MX2017000964A patent/MX370115B/es active IP Right Grant
- 2015-07-28 PE PE2017000103A patent/PE20170771A1/es unknown
- 2015-07-28 CA CA2953827A patent/CA2953827A1/en active Pending
- 2015-07-28 KR KR1020177002592A patent/KR20170065026A/ko not_active Withdrawn
- 2015-07-28 EA EA201692477A patent/EA035581B1/ru unknown
- 2015-07-28 EP EP15827485.2A patent/EP3174894B1/en active Active
- 2015-07-28 SG SG11201700378PA patent/SG11201700378PA/en unknown
- 2015-07-28 SG SG10201802098UA patent/SG10201802098UA/en unknown
- 2015-07-28 MD MDA20170020A patent/MD20170020A2/ro not_active Application Discontinuation
- 2015-07-28 US US14/811,578 patent/US9834586B2/en not_active Expired - Fee Related
- 2015-07-28 ES ES15827485T patent/ES2883158T3/es active Active
- 2015-07-28 TN TN2016000578A patent/TN2016000578A1/en unknown
- 2015-07-28 AU AU2015296640A patent/AU2015296640B2/en not_active Ceased
-
2016
- 2016-12-27 IL IL249793A patent/IL249793B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00311A patent/ZA201700311B/en unknown
- 2017-01-24 PH PH12017500153A patent/PH12017500153A1/en unknown
- 2017-01-25 DO DO2017000025A patent/DOP2017000025A/es unknown
- 2017-01-25 SV SV2017005367A patent/SV2017005367A/es unknown
- 2017-01-25 CL CL2017000201A patent/CL2017000201A1/es unknown
- 2017-01-25 EC ECIEPI20175276A patent/ECSP17005276A/es unknown
- 2017-01-25 CO CONC2017/0000614A patent/CO2017000614A2/es unknown
- 2017-11-01 US US15/801,198 patent/US20180134761A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,877 patent/US11358995B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12173060B2 (en) | Compositions and methods of use for treating metabolic disorders | |
| JP2016511752A5 (enExample) | ||
| CN105980400B (zh) | 生长分化因子15(gdf-15)构建体 | |
| CN102781960B (zh) | Hsa相关组合物及使用方法 | |
| CN106573966B (zh) | 用于治疗代谢异常的组合物和方法 | |
| CN102625811B (zh) | Fgf21突变体及其用途 | |
| JP5801807B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| JP2017538395A5 (enExample) | ||
| RU2015136440A (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| KR20020026558A (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| IL285716B (en) | Compacted molecules derived from colic toxin for oral delivery of biologically active cargo | |
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| WO2018166468A1 (zh) | IgG样长效免疫融合蛋白及其应用 | |
| JP2023096044A (ja) | 免疫調節融合タンパク質 | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| CN117186239A (zh) | 融合蛋白及其应用 | |
| CA3000697A1 (en) | Treatment of bile acid disorders | |
| JP2009510999A (ja) | キメラ治療剤 | |
| CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
| KR20250166188A (ko) | Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법 | |
| JP2024537239A (ja) | インターロイキン－１０ムテイン及びその融合タンパク質 | |
| CN113874393A (zh) | 对hbv包膜蛋白具有特异性的结合分子 | |
| WO2018219301A1 (zh) | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |